Randomized Phase II Clinical Study of Liposomal Irinotecan or Etoposide Combined With Carboplatin and Serplulimab as First-line Treatment for Extensive Stage Small Cell Lung Cancer.

This document provides information about a clinical trial, NCT06462105, which aims to study the treatment of small cell lung cancer (SCLC). SCLC is a highly malignant tumor with a high mortality rate, and the trial aims to compare the efficacy and safety of two different treatment regimens for first-line treatment of extensive stage SCLC. The study is not yet recruiting participants, and the estimated completion date is June 30, 2027. The document also includes keywords related to the study, such as antineoplastics, lung cancer, chemotherapy, and quality of life. [Extracted from the article]